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A B S T R A C T
Tetrahydrobiopterin (BH4) is a cofactor for the enzymes tyrosine hydroxylase and tryptophan hydroxylase, the
rate-limiting enzymes in the production of the neurotransmitters, dopamine and serotonin, respectively, in the
central nervous system (CNS). Administration of BH4 is used clinically within the management of persons with
genetic BH4 deﬁciencies, but the BH4 molecule does not cross the blood-brain barrier suﬃciently. CNSA-001 is a
pharmaceutical preparation of sepiapterin, a natural precursor of BH4 that induced larger increases in plasma
BH4 compared with administration of the same doses of BH4 itself in healthy volunteers in a randomized trial.
Here, we report the eﬀects of 7 days of once-daily treatment with CNSA-001 60mg/kg (n=6) or placebo (n=2)
on metabolites of the BH4 synthetic pathway and on biomarkers of the serotonin (5-hydroxyindoleacetic acid [5-
HIAA]) and dopamine (homovanillic acid [HVA]) pathways in cerebrospinal ﬂuid (CSF) in subjects from this
trial. There were no notable changes in any metabolite in placebo-treated subjects. Administration of CNSA-001
increased mean BH4 from 18.1 (SD 3.0) to 35.1 (10.0) nmol/L, and of dihydrobiopterin (BH2) from 2.1 (0.3) to
7.9 (1.5) nmol/L. Overall, administration of CNSA-001 had little eﬀect on mean levels (pre- vs. post-treatment)
of 5-HIAA (76.1 [SD 29.8] vs. 70.1 [23.1] nmol/L) or HVA (177.2 [66.5] vs. 184.8 [35.3]) nmol/L. One subject
with low 5-HIAA and HVA at baseline responded with approximately three-fold increases in CNS levels of these
metabolites after CNSA-001 treatment, with post-treatment levels within the range of those seen in other sub-
jects. Administration of CNSA-001 60mg/kg markedly increased levels of BH4 in the CNS of healthy volunteers,
with apparently little overall eﬀect in CNS levels of already normal key neurotransmitter metabolites.
1. Introduction
Tetrahydrobiopterin (BH4) is an essential cofactor for the enzyme,
phenylalanine hydroxylase, as well as hydroxylases that perform the
rate limiting step in the synthesis of monoamine neurotransmitters in
the central and peripheral nervous systems (tyrosine hydroxylase and
tryptophan hydroxylase) [1–3]. Subjects with defects in BH4 synthesis
often present with symptoms consistent with reduced function of these
neurotransmitter systems and may beneﬁt from treatment with the
products of these hydroxylases (levodopa and 5-hydroxytryptophan)
[4–6].
Increasing levels of BH4 within the brain would represent an alter-
native approach to the management of CNS symptoms in patients with
BH4 deﬁciencies. However, BH4 itself does not cross the blood brain
barrier suﬃciently, which limits the potential eﬃcacy of this approach
[7,8]. Administration of other components of the BH4 synthetic
pathway may provide an alternative approach. CNSA-001 is a novel
formulation of sepiapterin, a natural precursor of BH4. Oral adminis-
tration of CNSA-001 to healthy volunteers has been shown to induce
larger increases in plasma levels of BH4, compared with administration
of equivalent doses of BH4 itself, in healthy subjects in a randomized
clinical study [9]. We describe an exploratory study that evaluated the
eﬀects of oral CNSA-001, a pharmaceutical formulation of sepiapterin,
on levels of BH4, dihydrobiopterin (BH2, an intermediate in BH4 me-
tabolism) and metabolites of serotonin (5-hydroxyindoleacetic acid [5-
HIAA]) and dopamine (homovanillic acid [HVA]) in cerebrospinal ﬂuid
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(CSF) in healthy volunteers.
2. Methods
The data presented here are the results of an exploratory analysis in
one study cohort from a randomized, double-blind Phase I evaluation of
the pharmacokinetics of CNSA-001 in healthy volunteers. The study
design and main results of this study are described in detail elsewhere
[9]. Brieﬂy, subjects eligible for inclusion were adult (≥18 y) men or
non-pregnant women (55–100 kg), who were not taking antifolate
medication and who were free of signiﬁcant chronic illness or gastro-
intestinal disorders, and had not smoked tobacco for the previous two
weeks. Women were required to maintain adequate contraception. In-
formed consent was obtained from participants and ethical require-
ments for the conduct of clinical research in humans were met in full.
Measurements in CSF were made from subjects who received oral
treatment with CNSA-001 60mg/kg/day (n=6) or placebo (n=2)
once daily for seven days. The placebo used for this study was a for-
mulated suspension containing identical excipients as found in the drug
product formulation of CNSA-001 with the exception of substitution of
microcrystalline cellulose for active ingredient and the addition of
yellow dye #6 to match color. Cerebrospinal ﬂuid (CSF) was obtained
by lumbar puncture predose on day 1 and again following treatment on
Day 7 at the projected plasma Tmax for BH4. All lumbar punctures were
performed at the same time of day. All measurements of metabolites of
interest were conducted at MNG Laboratories, Atlanta, GA, USA.
Measurements of BH4 and BH2, were made using high performance li-
quid chromatography/mass spectrometry [9]. The concentrations of
neopterin in CSF were determined using high performance liquid
chromatography followed by sequential electrochemical and ﬂuores-
cence detection [10]. Concentrations in CSF of 5-HIAA and HVA were
measured following HPLC separation by electrochemical detection
[11]. Normal reference ranges used by this laboratory for metabolites of
interest in adults are: 5-HIAA 67–140 nmol/L; HVA 145–324 nmol/L;
BH4 10–30 nmol/L; neopterin 8–28 nmol/L. Methodologies for mea-
suring pterins are still evolving, and reference ranges for BH2 are not
available currently. Nevertheless, data on BH2 are included for com-
pleteness.
3. Results
Administration of CNSA-001 60mg/kg/day for 7 days led to an
approximate doubling of levels of BH4, an approximate tripling of levels
of BH2, and no change in neopterin concentration in CSF, with little or
no change caused by placebo (Table 1, Fig. 1). The BH4:BH2 ratio de-
creased, but there were only minor or no changes in the mean levels of
5-HIAA and HVA following treatment with CNSA-001 or placebo
(Table 1).
Fig. 1 shows medians, interquartile ranges and maximum and
minimum values of BH4, BH2, HVA and 5-HIAA before and after ad-
ministration of CNSA-001 for one week. Interestingly, pre-dose HVA
and 5-HIAA concentrations in one subject were about one-third of that
observed in the other subjects (55 nmol/L and 19 nmol/L, respectively),
but increased to 164 nmol/L and 50 nmol/L, respectively, which was
within the range of values in the other subjects.
4. Discussion
The main ﬁnding of this exploratory study was that oral adminis-
tration of CNSA-001 for one week induced marked increases in the le-
vels of BH4, along with its precursor, BH2, in the CSF of healthy vo-
lunteers. In eﬀect, CNSA-001 appeared to act as a prodrug for BH4 in
this setting.
Our study population was composed of healthy subjects with no
signs or symptoms of neurotransmitter deﬁciency. There was little ef-
fect of CNSA-001 on mean values of HVA or 5-HIAA. This implied a lack
of overall eﬀect of CNSA-001 on the activity of CNS pathways mediated
by serotonin or dopamine, despite the approximate doubling in BH4
concentration in the CSF. Alternatively, this provides evidence that
prolonged exposure to increased concentrations of BH4 and BH2 in the
CSF does not enhance the metabolism of monoamines in healthy per-
sons with normal concentrations of neurotransmitters and normal
functioning dopamine and serotonin regulation. These ﬁndings were
consistent with those of the overall study, in which no adverse events
suggestive of neurotransmitter disturbances were observed [9].
The marked increase in 5-HIAA and HVA in one subject with ab-
normally low levels of these metabolites at baseline was interesting, as
treatment with CNSA-001 appeared to normalize the concentrations of
these metabolites in this patient's CSF. BH4 levels in CSF in this subject
also responded markedly to treatment with CNSA-001. Indeed, the BH4
level in the CSF of this subject was lower than in any other subject at
baseline, and higher than any other subject after treatment.
The small size of this exploratory study was its most obvious lim-
itation, particularly as only two subjects received placebo. Our results
must be interpreted with caution, although sepiapterin and placebo
were administered in a prospective, double-blind, randomized manner.
5. Conclusions
Oral administration of CNSA-001, a pharmaceutical formulation of
sepiapterin, induced marked increases in the level of BH4 in CSF, with
no overall eﬀect on the levels of metabolites of serotonin and dopamine
when given to healthy volunteers. Further study will be required to
evaluate the eﬀects of CNSA-001 on CNS neurotransmitter function in
patients with BH4 deﬁciencies.
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Table 1
Exploratory data from measurements in cerebrospinal ﬂuid predose and fol-
lowing seven days of administration of CNSA-001 or placebo.
CNSA-001 60mg/kg/day
(n=6)
Placeboa (n=2)
Mean BH4 nmol/L (SD)
Baseline 18.1 (3.0) 12.8; 13.5
Day 7 35.1 (10.0) 13.5; 13.1
Mean change from baseline (SD) 17.0 (12.2)
Mean BH2 nmol/L (SD)
Baseline 2.1 (0.3) 2.5; 1.5
Day 7 7.9 (1.5) 2.5; 1.5
Mean change from baseline (SD) 5.7 (1.5)
Mean 5-HIAA nmol/L (SD)
Baseline 76.1 (29.8) 49.6; 75.0
Day 7 70.1 (23.1) 43.7; 55.5
Mean change from baseline (SD) –6.0 (24.0)
Mean HVA nmol/L (SD)
Baseline 177.2 (66.5) 123.2; 152.5
Day 7 184.8 (35.3) 128.7; 140.2
Mean change from baseline (SD) 7.6 (65.8)
Mean neopterin nmol/L (SD)
Baseline 15.0 (4.1) 25.0; 12.0
Day 7 14.9 (3.7) 24.6; 10.2
Mean change from baseline (SD) –0.04 (1.6)
Treatments were given for 7 days. Measurements on day 7 were made±30min
from the time of BH4 Tmax. Measurements were made in 6 and 2 subjects ran-
domly assigned to CNSA-001 and placebo, respectively. 5-HIAA: 5-hydro-
xyindoleacetic acid; HVA: homovanillic acid.
a
Single values.
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Fig. 1. Exploratory data from measurements of pterins and
biogenic amines, before and after 7 days of CNSA-001 (se-
piapterin) administration, in cerebrospinal ﬂuid (CSF) from
healthy volunteers. Bars show maximum and minimum va-
lues; boxes show median and interquartile ranges. Diamonds
show values of HVA and 5-HIAA from one subject who had
unusually low levels of these metabolites in CSF at baseline
but responded with substantial increases in these metabolites
after treatment with CNSA-001. Shaded areas show labora-
tory reference ranges for each metabolite (not available for
BH2, see text).
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